CRDF
Cardiff Oncology, Inc.
There isn't enough reported data to score CRDF yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CRDF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CRDF's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRDF PE Valuation
CRDF has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRDF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CRDF's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRDF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.55 | +$0.25 |
| Q2 2026 | -$0.60 | +$0.28 |
| Q1 2026 | -$0.67 | +$0.26 |
| Q4 2025 | -$0.69 | +$0.26 |
| Q3 2025 | -$0.80 | +$0.14 |
| Q2 2025 | -$0.88 | +$0.03 |
| Q1 2025 | -$0.93 | -$0.03 |
| Q4 2024 | -$0.95 | -$0.02 |
CRDF is still losing money, but far less than before: $0.55 per share over the past year, against $2.80 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRDF on earnings quality, reporting a profit while its opponent remains loss making.
CRDF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $171K | +43% |
| Q2 2026 | $104K | -14% |
| Q1 2026 | $41K | -62% |
| Q4 2025 | $243K | +61% |
| Q3 2025 | $120K | -27% |
| Q2 2025 | $121K | -26% |
| Q1 2025 | $109K | -47% |
| Q4 2024 | $151K | -3.2% |
CRDF's revenue is growing: $171,000 last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5391% | +4587 points |
| Q2 2026 | -9245% | +2967 points |
| Q1 2026 | -31341% | -18147 points |
| Q4 2025 | -3221% | +5105 points |
| Q3 2025 | -9978% | -2341 points |
| Q2 2025 | -12212% | -4516 points |
| Q1 2025 | -13195% | -7861 points |
| Q4 2024 | -8326% | -1703 points |
CRDF's operating margin was −5391% last quarter, up 4587 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CRDF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CRDF on profitability, with a higher operating margin.
CRDF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.9M | +$974K |
| Q4 2025 | -$6M | +$4.3M |
| Q3 2025 | -$10.9M | -$396K |
| Q4 2024 | -$10.3M | -$3.1M |
| Q3 2024 | -$10.5M | -$2.2M |
| Q2 2024 | -$9.2M | -$1.8M |
| Q1 2024 | -$7.8M | +$847K |
| Q4 2023 | -$7.1M | +$2.3M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with CRDF at down 29%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
CRDF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +7.8M shares |
| 1 year | +14% | +9.3M shares |
| 3 years | +71% | +31.5M shares |
| 5 years | +97% | +37.4M shares |
| Available history | +669% | +66.3M shares |
CRDF has 76M diluted shares, up 14% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CRDF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRDF Net Leverage
CRDF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRDF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CRDF's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRDF PE vs Healthcare Sector
CRDF has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRDF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.96 | 24% below |
| 20 week MA | $1.01 | 28% below |
| 50 week MA | $1.57 | 54% below |
| 100 week MA | $2.35 | 69% below |
| 200 week MA | $2.29 | 68% below |
CRDF is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRDF on trend strength, trading above more of its moving averages.
CRDF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $18.9 | +1377% |
| 2021 | $18.9 | $6.45 | -66% |
| 2022 | $6.45 | $1.26 | -80% |
| 2023 | $1.26 | $1.48 | +17% |
| 2024 | $1.48 | $4.32 | +192% |
| 2025 | $4.32 | $3.17 | -27% |
| 2026 YTD | $3.17 | $0.73 | -77% |
CRDF's yearly returns have swung widely, from +1377% in 2020 to −80% in 2022. It's down 77% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRDF on returns for 2026, with the stronger performance.